UY26861A1 - Composición de eletriptan en forma de partículas - Google Patents
Composición de eletriptan en forma de partículasInfo
- Publication number
- UY26861A1 UY26861A1 UY26861A UY26861A UY26861A1 UY 26861 A1 UY26861 A1 UY 26861A1 UY 26861 A UY26861 A UY 26861A UY 26861 A UY26861 A UY 26861A UY 26861 A1 UY26861 A1 UY 26861A1
- Authority
- UY
- Uruguay
- Prior art keywords
- composition
- eletriptan
- pharmaceutical composition
- core
- particles
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electroluminescent Light Sources (AREA)
- Luminescent Compositions (AREA)
Abstract
Esta invención proporciona una composición farmacéutica en forma de partículas, adecuada para la administración por vía oral, que incluye un núcleo que contiene eletriptan o una sal farmacéuticamente aceptable del mismo, estando revestido el núcleo con un revestimiento insoluble en agua, y permeable, que incluyen uno o más copolímeros acrílicos que contienen grupos de metacrilato de trimetilamonioetilo, y siendo dicha composición capaz de conseguir un curso sigmoideo de liberación controlada del fármaco. Esta composición farmacéutica es particularmente útil en la prevención de la recurrencia de la migrana.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0018968.8A GB0018968D0 (en) | 2000-08-02 | 2000-08-02 | Particulate composition |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26861A1 true UY26861A1 (es) | 2002-02-28 |
Family
ID=9896843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26861A UY26861A1 (es) | 2000-08-02 | 2001-07-30 | Composición de eletriptan en forma de partículas |
Country Status (38)
Country | Link |
---|---|
US (1) | US20020034545A1 (es) |
EP (1) | EP1365748B1 (es) |
JP (1) | JP2004505034A (es) |
KR (1) | KR20030024820A (es) |
CN (1) | CN1630511A (es) |
AP (1) | AP2001002233A0 (es) |
AR (1) | AR030099A1 (es) |
AT (1) | ATE308978T1 (es) |
AU (1) | AU2001270932A1 (es) |
BG (1) | BG107361A (es) |
BR (1) | BR0112839A (es) |
CA (1) | CA2417887C (es) |
CZ (1) | CZ2003241A3 (es) |
DE (1) | DE60114887T2 (es) |
EA (1) | EA200300110A1 (es) |
EC (1) | ECSP034451A (es) |
EE (1) | EE200300051A (es) |
ES (1) | ES2250429T3 (es) |
GB (1) | GB0018968D0 (es) |
GT (1) | GT200100149A (es) |
HR (1) | HRP20030036A2 (es) |
HU (1) | HUP0301453A2 (es) |
IL (1) | IL153494A0 (es) |
IS (1) | IS6649A (es) |
MA (1) | MA26934A1 (es) |
MX (1) | MXPA03000999A (es) |
NO (1) | NO20030498D0 (es) |
NZ (1) | NZ522976A (es) |
OA (1) | OA12348A (es) |
PA (1) | PA8523101A1 (es) |
PE (1) | PE20020385A1 (es) |
PL (1) | PL359847A1 (es) |
SK (1) | SK1082003A3 (es) |
SV (1) | SV2002000574A (es) |
TN (1) | TNSN01115A1 (es) |
UY (1) | UY26861A1 (es) |
WO (1) | WO2002009675A1 (es) |
ZA (1) | ZA200300868B (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040022853A1 (en) * | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
CA2510152C (en) * | 2002-12-16 | 2013-04-02 | Chx Technologies, Inc. | Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing |
BRPI0409127A (pt) | 2003-04-11 | 2006-03-28 | Pfizer | combinação farmacêutica compreendendo eletriptano e bicarbonato de sódio |
GB2407498B (en) * | 2003-10-30 | 2008-06-11 | Cipla Ltd | Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient |
WO2005120456A2 (en) * | 2004-06-09 | 2005-12-22 | Pfizer Limited | Formulation of eletriptan |
WO2006013431A1 (en) * | 2004-07-29 | 2006-02-09 | Pfizer Limited | Stable controlled-release pharmaceutical formulation of eletriptan |
EP1847268A1 (en) * | 2005-01-31 | 2007-10-24 | Kyorin Pharmaceutical Co., Ltd. | Multiple unit oral sustained release preparation and process for production of the same |
WO2007016948A1 (de) | 2005-08-10 | 2007-02-15 | Add Advanced Drug Delivery Technologies Ltd. | Orales präparat mit kontrollierter freisetzung |
US20070134322A1 (en) * | 2005-12-14 | 2007-06-14 | Forest Laboratories, Inc. | Modified and pulsatile release pharmaceutical formulations of escitalopram |
CA2597740C (en) * | 2006-04-26 | 2012-10-16 | Supernus Pharmaceuticals, Inc. | Modified-release preparations containing oxcarbazepine and derivatives thereof |
WO2008115797A1 (en) * | 2007-03-16 | 2008-09-25 | Pavo, Inc. | Therapeutic compositions and methods |
WO2009015336A2 (en) | 2007-07-25 | 2009-01-29 | Biolex Therapeutics, Inc. | Controlled release interferon drug products and treatment of hcv infection using same |
ES2671036T3 (es) | 2009-11-16 | 2018-06-04 | Evonik Röhm Gmbh | Un proceso de conversión de un copolímero de (met)acrilato sólido en una forma dispersa por medio de un agente dispersante |
WO2016040358A1 (en) * | 2014-09-09 | 2016-03-17 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
GB201716716D0 (en) * | 2017-10-12 | 2017-11-29 | Univ Of Hertfordshire Higher Education Corporation | Method for coating particles |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2624732B1 (fr) * | 1987-12-21 | 1991-02-15 | Synthelabo | Formulation pharmaceutique a liberation prolongee |
US5411745A (en) * | 1994-05-25 | 1995-05-02 | Euro-Celtique, S.A. | Powder-layered morphine sulfate formulations |
GB9417310D0 (en) * | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
GB9825988D0 (en) * | 1998-11-27 | 1999-01-20 | Pfizer Ltd | Indole derivatives |
GB9922963D0 (en) * | 1999-09-28 | 1999-12-01 | Pfizer Ltd | Polymorphic salt |
FR2795962B1 (fr) * | 1999-07-08 | 2003-05-09 | Prographarm Laboratoires | Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif |
US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
-
2000
- 2000-08-02 GB GBGB0018968.8A patent/GB0018968D0/en not_active Ceased
-
2001
- 2001-07-18 NZ NZ522976A patent/NZ522976A/en unknown
- 2001-07-18 AP APAP/P/2001/002233A patent/AP2001002233A0/en unknown
- 2001-07-18 HU HU0301453A patent/HUP0301453A2/hu unknown
- 2001-07-18 ES ES01949819T patent/ES2250429T3/es not_active Expired - Lifetime
- 2001-07-18 DE DE60114887T patent/DE60114887T2/de not_active Expired - Lifetime
- 2001-07-18 EE EEP200300051A patent/EE200300051A/xx unknown
- 2001-07-18 WO PCT/IB2001/001279 patent/WO2002009675A1/en active IP Right Grant
- 2001-07-18 AU AU2001270932A patent/AU2001270932A1/en not_active Abandoned
- 2001-07-18 PL PL35984701A patent/PL359847A1/xx not_active Application Discontinuation
- 2001-07-18 OA OA1200300020A patent/OA12348A/en unknown
- 2001-07-18 JP JP2002515228A patent/JP2004505034A/ja active Pending
- 2001-07-18 CN CNA018134041A patent/CN1630511A/zh active Pending
- 2001-07-18 IL IL15349401A patent/IL153494A0/xx unknown
- 2001-07-18 EA EA200300110A patent/EA200300110A1/ru unknown
- 2001-07-18 AT AT01949819T patent/ATE308978T1/de not_active IP Right Cessation
- 2001-07-18 BR BR0112839-6A patent/BR0112839A/pt not_active Application Discontinuation
- 2001-07-18 EP EP01949819A patent/EP1365748B1/en not_active Expired - Lifetime
- 2001-07-18 SK SK108-2003A patent/SK1082003A3/sk not_active Application Discontinuation
- 2001-07-18 CZ CZ2003241A patent/CZ2003241A3/cs unknown
- 2001-07-18 CA CA002417887A patent/CA2417887C/en not_active Expired - Fee Related
- 2001-07-18 KR KR10-2003-7001402A patent/KR20030024820A/ko not_active Application Discontinuation
- 2001-07-18 MX MXPA03000999A patent/MXPA03000999A/es active IP Right Grant
- 2001-07-25 US US09/912,774 patent/US20020034545A1/en not_active Abandoned
- 2001-07-25 PA PA20018523101A patent/PA8523101A1/es unknown
- 2001-07-25 GT GT200100149A patent/GT200100149A/es unknown
- 2001-07-30 SV SV2001000574A patent/SV2002000574A/es not_active Application Discontinuation
- 2001-07-30 UY UY26861A patent/UY26861A1/es not_active Application Discontinuation
- 2001-08-01 PE PE2001000770A patent/PE20020385A1/es not_active Application Discontinuation
- 2001-08-01 AR ARP010103668A patent/AR030099A1/es unknown
- 2001-08-01 TN TNTNSN01115A patent/TNSN01115A1/fr unknown
-
2002
- 2002-12-05 IS IS6649A patent/IS6649A/is unknown
- 2002-12-06 BG BG107361A patent/BG107361A/bg unknown
-
2003
- 2003-01-21 HR HR20030036A patent/HRP20030036A2/hr not_active Application Discontinuation
- 2003-01-23 MA MA27009A patent/MA26934A1/fr unknown
- 2003-01-24 EC EC2003004451A patent/ECSP034451A/es unknown
- 2003-01-31 NO NO20030498A patent/NO20030498D0/no unknown
- 2003-01-31 ZA ZA200300868A patent/ZA200300868B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26861A1 (es) | Composición de eletriptan en forma de partículas | |
CY1106072T1 (el) | Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος | |
ATE391496T1 (de) | Geschmacksmaskierte pharmazeutische formulierungen | |
DE60237372D1 (de) | Magenretentionssystem mit kontrollierter arzneimittelfreisetzung | |
BR0312347A (pt) | Composição farmacêutica oral, usos da espessura de revestimento de um material de revestimento dependente do ph de dissolução, de um material de revestimento, e de um material de polimetacrilato | |
DOP2001000229A (es) | Forma de dosificación de fármaco activada por hidrogel | |
IL173078A0 (en) | Multiparticle pharmaceutical dosage form containing a mucoadhesively formulated peptide or protein active substances method for producing said pharmaceutical dosage form | |
CO5261492A1 (es) | Formas de dosificacion de liberacion controlada que comprenden zolpidem o sales del mismo | |
ATE213629T1 (de) | Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe | |
CY1112517T1 (el) | Φαρμακοτεχνικες μορφες τροποποιημενης αποδεσμευσης μιας τουλαχιστον μορφης τραμαδολης | |
ES2531215T3 (es) | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos | |
KR950031052A (ko) | 알푸조신 히드로클로라이드의 서방성 투약형태 | |
CO6140021A2 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
DK1345595T3 (da) | Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse | |
BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
DE69927374D1 (de) | Entzündungshemmende pharmazeutische formulierungen | |
ATE367153T1 (de) | Multipartikuläre arzneizusammensetzungen mit gesteuerter wirkstoffabgabe enthaltend selektive inhibitoren der serotoninwiederaufnahme | |
CR6858A (es) | Composiciones de eletriptan en forma de particulas que muestra el curso sigmoideo de liberacion controlada | |
DOP2001000223A (es) | Composición de eletriptan en forma de particula | |
UA74335C2 (uk) | Мультичастинкова композиція контрольованого вивільнення флувоксаміну та спосіб лікування станів, які лікуються за допомогою селективних інгібіторів зворотного захоплення серотоніну | |
TR200400812T3 (tr) | KanserÁtedavisiÁiçinÁretinoidÁreseptörÁligandlarınınÁveÁseçilenÁsitotoksikÁmaddelerinÁsinerjistikÁkombinasyonları | |
UY27122A1 (es) | Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona | |
GT199700143A (es) | Forma de dosificacion farmaceutica que enmascara el sabor y que se libera rapidamente. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20140625 |